Loading clinical trials...
Loading clinical trials...
This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
NCT06347068 · Breast Cancer, Relapse, and more
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT07655934 · Breast Cancer
NCT07436078 · Female Breast Cancer, Prostate Cancer, and more
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
Local Institution
Kurralta Park, South Australia
Local Institution
Frankston, Victoria
Local Institution
Geelong, Victoria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions